Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Female Sexual Dysfunction Guidance Should Be Revised, Intrinsa Cmte. Says

Executive Summary

FDA should consider revising the recommended primary endpoint for female sexual dysfunction clinical trials, members of the Reproductive Health Drugs Advisory Committee said Dec. 2

You may also be interested in...



A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors

Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.

Full Safety Data For Female Sexual Disorder Drugs Could Come Post-Approval

Sponsors of testosterone therapies for hypoactive sexual desire disorder may be able to pursue NDA approval with some safety data submitted pre-approval and further safety data collected post-approval

Full Safety Data For Female Sexual Disorder Drugs Could Come Post-Approval

Sponsors of testosterone therapies for hypoactive sexual desire disorder may be able to pursue NDA approval with some safety data submitted pre-approval and further safety data collected post-approval

UsernamePublicRestriction

Register

PS045091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel